CAJ | 학술논문

目的：探讨英夫利西单抗对克罗恩病的疗效和安全性。方法回顾性分析2013年5月至2015年3月于福建医科大学附属第一医院使用英夫利西治疗13例克罗恩病患者的临床和内镜资料，观察治疗第14周、随访终点的BEST-CDAI评分、CRP、ESR、ALB、SES-CD评分，并记录不良反应。结果研究对象男7例，女6例，平均年龄（26.46±12.45）岁，中位病程2.5年；治疗第14周，13例患者的CDAI评分、CRP、ESR均下降，ALB升高，差异有统计学意义（P<0.05），所有患者获得临床缓解（100%）；随访终点，13例患者的CDAI评分下降， ALB升高，差异有统计学意义（P<0.05），维持缓解率达90%。8例患者IFX治疗后复查肠镜，5例（62.5%）患者SES-CD下降≥1分，其中2例（25%）达到黏膜完全愈合。不良反应发生率约3.3%，主要包括过敏和感染。结论 IFX对克罗恩病患者的治疗是有效、安全的。
목적：탐토영부리서단항대극라은병적료효화안전성。방법회고성분석2013년5월지2015년3월우복건의과대학부속제일의원사용영부리서치료13례극라은병환자적림상화내경자료，관찰치료제14주、수방종점적BEST-CDAI평분、CRP、ESR、ALB、SES-CD평분，병기록불량반응。결과연구대상남7례，녀6례，평균년령（26.46±12.45）세，중위병정2.5년；치료제14주，13례환자적CDAI평분、CRP、ESR균하강，ALB승고，차이유통계학의의（P<0.05），소유환자획득림상완해（100%）；수방종점，13례환자적CDAI평분하강， ALB승고，차이유통계학의의（P<0.05），유지완해솔체90%。8례환자IFX치료후복사장경，5례（62.5%）환자SES-CD하강≥1분，기중2례（25%）체도점막완전유합。불량반응발생솔약3.3%，주요포괄과민화감염。결론 IFX대극라은병환자적치료시유효、안전적。
Objective To analyze efficacy and safety of Infliximab(IFX) on Crohn's disease(CD).Methods From May 2013 to March 2015, the clinical and endoscopic data of 13 CD patients with IFX treatment in the first affiliated hospital of Fujian medical university were retrospectively analyzed. Crohn's disease active index (CDAI), C reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin (ALB) and simple endoscopic score for Crohn's disease (SES-CD) were investigated at week 14th after IFX injection and the end of follow-up of this study. Adverse reaction was evaluated.Results Thirteen patients (7 male, 6 female) with the average age of(26.46±12.45) years and the mean disease course of 2.5 years were included in the analysis. At week 14th, the levels of the scores of CDAI, CRP and ESR all decreased significantly, and the level of ALB increased significantly compared with the before the treatment (P<0.05). All patients achieved clinical remission and the remission rate was 100%. By the end of follow-up, the level of the scores of CDAI decreased significantly and the level of ALB increased significantly (P<0.05). The rate of maintain remission was 90%. Eight patients were reviewed by colonoscopic examination after IFX treatment. Five patients (62.5%) decreased the scores of SES-CD and two patients (25%) attained mucosal healing. The rate of adverse events was about 3.3%, including hypersensitirity reaction and infective.Conclusion IFX has good curative effects and safety in the treatment of CD.